NKMax America, a biotechnology company, has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the safety and tolerability of SNK01, the company’s autologous natural killer cell therapy in combination with avelumab (BAVENCIO), a human anti-PD-L1 therapy co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc., in solid tumors.   Under the terms of this agreement, NKMax America will be the study...